A196300 Stock Overview
A bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Anygen Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,090.00 |
| 52 Week High | ₩19,000.00 |
| 52 Week Low | ₩9,000.00 |
| Beta | 0.72 |
| 11 Month Change | 8.38% |
| 3 Month Change | 14.55% |
| 1 Year Change | -1.40% |
| 33 Year Change | -11.38% |
| 5 Year Change | 59.39% |
| Change since IPO | 11.83% |
Recent News & Updates
Shareholder Returns
| A196300 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.1% | -1.5% | 0.9% |
| 1Y | -1.4% | 23.1% | -3.4% |
Return vs Industry: A196300 underperformed the KR Biotechs industry which returned 23.1% over the past year.
Return vs Market: A196300 exceeded the KR Market which returned -3.4% over the past year.
Price Volatility
| A196300 volatility | |
|---|---|
| A196300 Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in KR Market | 11.6% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A196300's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A196300's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Jae Il Kim | www.anygen.com |
Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently under pre-clinical development phase; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria, currently under pre-clinical development phase.
Anygen Co., Ltd. Fundamentals Summary
| A196300 fundamental statistics | |
|---|---|
| Market cap | ₩84.59b |
| Earnings (TTM) | -₩8.67b |
| Revenue (TTM) | ₩6.12b |
13.8x
P/S Ratio-9.8x
P/E RatioIs A196300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A196300 income statement (TTM) | |
|---|---|
| Revenue | ₩6.12b |
| Cost of Revenue | ₩9.48b |
| Gross Profit | -₩3.37b |
| Other Expenses | ₩5.30b |
| Earnings | -₩8.67b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.44k |
| Gross Margin | -55.09% |
| Net Profit Margin | -141.76% |
| Debt/Equity Ratio | 91.6% |
How did A196300 perform over the long term?
See historical performance and comparison